New drug combo with chemo and radiation for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have rectal cancer that is stage II or III (has not spread beyond the pelvis) and is the common type (pMMR/MSS).
- You cannot have had any prior treatment for this rectal cancer (like chemo, radiation, or surgery).
- You must be in generally good health (able to do daily activities) with adequate blood counts and liver/kidney function.
- You should not have certain severe heart conditions, active infections, or autoimmune diseases.
- If you are able to become pregnant, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
Hear when a new Local Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.